ライフサイエンスコーパス: catheter ablation

1 ction of patient-centered outcomes following catheter ablation.

2 rug therapy, 301 (27.5%) ultimately received catheter ablation.

3 ales; 39% persistent AF) undergoing first AF catheter ablation.

4 es in pediatric patients with CHD undergoing catheter ablation.

5 were enrolled, and 127 underwent mapping and catheter ablation.

6 ignificant subgroup of patients referred for catheter ablation.

7 a structurally normal heart and the role of catheter ablation.

8 0 mm Hg) treatment before their scheduled AF catheter ablation.

9 reentrant tachycardia and were treated with catheter ablation.

10 ith paroxysmal atrial fibrillation receiving catheter ablation.

11 nd its association with clinical outcomes of catheter ablation.

12 roperties were prospectively tested to guide catheter ablation.

13 sk for recurrent atrial arrhythmia requiring catheter ablation.

14 achycardia (VT) was rendered noninducible by catheter ablation.

15 r hemodynamic instability prevents emergency catheter ablation.

16 the phrenic nerve (PN) can hinder successful catheter ablation.

17 uential (n=9) or simultaneous (n=5) unipolar catheter ablation.

18 ssociated with reduced freedom from AF after catheter ablation.

19 r the prediction of rhythm outcomes after AF catheter ablation.

20 c were associated with rhythm outcomes after catheter ablation.

21 ce of spontaneous resolution and the role of catheter ablation.

22 /-10 years; 35% persistent AF) undergoing AF catheter ablation.

23 for the prediction of rhythm outcomes after catheter ablation.

24 (AF) occur in up to 30% within 1 year after catheter ablation.

25 s may influence the long-term outcomes after catheter ablation.

26 ation time (DAT), on AF recurrence following catheter ablation.

27 osine can unmask dormant AP conduction after catheter ablation.

28 and hemorrhagic events after radiofrequency catheter ablation.

29 has been associated with poor outcomes of AF catheter ablation.

30 ic drug levels are reached to safely perform catheter ablation.

31 d to recurrent ventricular tachycardia after catheter ablation.

32 responders subsequently underwent successful catheter ablation.

33 localize the anatomic site of origin before catheter ablation.

34 4/55) received immunosuppressive therapy and catheter ablation.

35 Of the patients assigned to catheter ablation, 1006 (90.8%) underwent the procedure.

36 incidence of LVAs in patients undergoing AF catheter ablation, (2) the distribution of LVAs within t

37 At 24 hours after the radiofrequency catheter ablation, 20 (74%) patients had at least 1 new

38 the training set AF terminated in 81% during catheter ablation, 77% were in sinus rhythm after 6 year

39 During the catheter ablation, a mean number of 10.4+/-7.4 radiofreq

40 After catheter ablation, a programmed ventricular stimulation

41 nts were randomly assigned to receive either catheter ablation (ablation group) with continuation of

42 Catheter ablation allowed for resumption of biventricula

43 Patients were randomly assigned to catheter ablation alone (n = 158) or catheter ablation c

44 sion group compared with 38% (60/158) in the catheter ablation alone group (difference, 11.2% [95% CI

45 infusion to catheter ablation, compared with catheter ablation alone, increased the likelihood of rem

46 on added to catheter ablation, compared with catheter ablation alone, significantly increased the lik

47 cause death between patients treated with AF catheter ablation and antiarrhythmic medications only.

48 for AF termination and long-term success of catheter ablation and compared them with clinical predic

49 model to estimate the costs and benefits of catheter ablation and medical management in patients wit

50 and on the therapeutic efficacy of targeted catheter ablation and mitral valve surgery in reducing t

51 to eliminate or modify the triggers through catheter ablation and ultimately an implantable cardiove

52 time of procedures including cardioversion, catheter ablation, and device implantation.

53 risk of atrial fibrillation recurrence after catheter ablation, and subsequent multimodality imaging

54 Either medical treatment or catheter ablation are considered first-line therapies in

55 commend pulmonary-vein isolation by means of catheter ablation as treatment for drug-refractory parox

56 device who underwent ventricular arrhythmia catheter ablation at 9 tertiary centers were included.

57 ts (age 54+/-11 years, 73% males) undergoing catheter ablation at our institutions were included in t

58 Catheter ablation at these sites, in conjunction with pu

59 Among patients with AF undergoing catheter ablation, atrial tissue fibrosis estimated by d

60 gs and 2+/-1 previous endocardial/epicardial catheter ablation attempts underwent transcoronary ethan

61 ng Persistent Atrial Fibrillation Undergoing Catheter Ablation [BELIEF]; NCT01362738).

62 Clinical Question: Is catheter ablation better than antiarrhythmic drugs for t

63 d lower recurrence rates than radiofrequency catheter ablation, better catheter stability, and lesser

64 improve outcomes in atrial fibrillation (AF) catheter ablation, but the use of this technique remains

65 h more costly inpatient therapies such as AF catheter ablation, but this finding was associated with

66 ting >30 seconds, determined 3 months beyond catheter ablation by a blinded end-point evaluation.

67 goal of this study was to determine whether catheter ablation (CA) for AF could improve LVSD compare

68 Catheter ablation (CA) for atrial fibrillation (AF) has

69 The limited effectiveness of endocardial catheter ablation (CA) for persistent and long-standing

70 brillation (VLRAF) occuring >12 months after catheter ablation (CA) in apparently "cured" patients co

71 icacy and safety of antiarrhythmic drugs and catheter ablation (CA) in the treatment of ventricular t

72 Whether catheter ablation (CA) is superior to amiodarone (AMIO)

73 The effects of time to referral for catheter ablation (CA) of scar-related ventricular tachy

74 Catheter ablation (CA) of ventricular tachycardia (VT) i

75 Catheter ablation (CA) of ventricular tachycardia (VT) i

76 ls to examine the safety and the efficacy of catheter ablation (CA) when compared with antiarrhythmic

77 several randomized clinical trials comparing catheter ablation (CA) with medical therapy (MT) in pati

78 imited ability to predict recurrent VT after catheter ablation (CA).

79 elevated risk for sudden cardiac death, and catheter ablation can be used as adjunctive therapy to t

80 e hypothesized that open irrigated microwave catheter ablation can create deep myocardial lesions end

81 evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF an

82 Although catheter ablation can restore normal heart rhythms, pati

83 a single procedure was 49.2% (91/185) in the catheter ablation combined with vein of Marshall ethanol

84 gned to catheter ablation alone (n = 158) or catheter ablation combined with vein of Marshall ethanol

85 s was significantly greater in patients with catheter ablation compared with 21 matched controls duri

86 12 months was greater for those treated with catheter ablation compared with antiarrhythmic medicatio

87 AF burden was significantly less in catheter ablation compared with drug-therapy patients ac

88 The incremental cost-effectiveness ratio for catheter ablation compared with medical management was $

89 and hypertension, renal denervation added to catheter ablation, compared with catheter ablation alone

90 tion of vein of Marshall ethanol infusion to catheter ablation, compared with catheter ablation alone

91 Among patients with AF, the strategy of catheter ablation, compared with medical therapy, did no

92 tients with symptomatic atrial fibrillation, catheter ablation, compared with medical therapy, led to

93 al and persistent AF (undergoing their first catheter ablation) conducted between August 2010 and Aug

94 Safe and successful radiofrequency catheter ablation depends on creation of transmural lesi

95 However, catheter ablation did reduce the total number of ICD int

96 rediction of arrhythmia recurrences after AF catheter ablation during long-term follow-up.

97 Patients received catheter ablation for AF and pharmacological treatment f

98 ot reduce atrial arrhythmia recurrence after catheter ablation for AF but resulted in more hypotensio

99 with recurrence of atrial arrhythmias after catheter ablation for AF.

100 lation (ERAF) is common after radiofrequency catheter ablation for AF.

101 factors of esophageal injury (EI) caused by catheter ablation for AF.

102 ted in the genesis of OT arrhythmias, making catheter ablation for arrhythmias beyond the right ventr

103 The optimal timing of catheter ablation for atrial fibrillation (AF) in refere

104 Catheter ablation for atrial fibrillation (AF) using poi

105 edisposes esophagus to thermal injury during catheter ablation for atrial fibrillation (AF).

106 onsiderations particularly as the demand for catheter ablation for atrial fibrillation continues to r

107 Radiofrequency catheter ablation for atrial fibrillation has become an

108 mized clinical trials have demonstrated that catheter ablation for atrial fibrillation in patients wi

109 udies reporting the outcomes associated with catheter ablation for atrial fibrillation stratified by

110 t failure admissions in the CASTLE-AF study (Catheter Ablation for Atrial Fibrillation With Heart Fai

111 blished success rates such as radiofrequency catheter ablation for atrial fibrillation.

112 between the study arms significantly favored catheter ablation for both the primary end point and all

113 Eighty-seven patients underwent catheter ablation for drug-refractory VT.

114 aborative database of patients who underwent catheter ablation for infarct-related VT.

115 Patients undergoing catheter ablation for papillary muscle, fascicular, or m

116 validates the use of a blanking period after catheter ablation for paroxysmal atrial fibrillation but

117 The success rate of catheter ablation for persistent atrial fibrillation (AF

118 study aimed to determine 5-year efficacy of catheter ablation for persistent atrial fibrillation (AF

119 pendent predictors of VT-free survival after catheter ablation for post-myocardial infarction ventric

120 ighly morbid condition that can result after catheter ablation for PV isolation.

121 an age 48 +/- 16 years; 83% male) undergoing catheter ablation for scar-related right ventricular VT,

122 emerged, sometimes used in combination with catheter ablation for the treatment of the atrial fibril

123 Catheter ablation for ventricular arrhythmia (VA) near t

124 Catheter ablation for ventricular tachycardia (VT) reduc

125 Catheter ablation for ventricular tachycardia and premat

126 lity constitute significant end points after catheter ablation for VT.

127 cular outflow tract (LVOT) sometimes require catheter ablation from both the endocardial and epicardi

128 cular outflow tract (LVOT) sometimes require catheter ablation from the endocardial and epicardial si

129 ial and simultaneous unipolar radiofrequency catheter ablation from the endocardial and epicardial si

130 the discretion of the investigators, for the catheter ablation group (n = 1108) and standard rhythm a

131 The catheter ablation group (n = 1108) underwent pulmonary v

132 FEQT summary score was more favorable in the catheter ablation group than the drug therapy group at 1

133 I frequency score was more favorable for the catheter ablation group than the drug therapy group at 1

134 SI severity score was more favorable for the catheter ablation group than the drug therapy group at 1

135 .001) were both significantly reduced in the catheter ablation group.

136 Radiofrequency catheter ablation has become the treatment strategy of c

137 atrial fibrillation despite medical therapy, catheter ablation has been shown to substantially reduce

138 Formation of microemboli during catheter ablation has been suggested as a cause for asym

139 Catheter ablation has brought major advances in the mana

140 fibrillation (AF), enlarged atria, or failed catheter ablation have advanced AF and may require more

141 as 57 were assigned ICD implantation without catheter ablation (ICD-only group: 66+/-8 years; 46 men)

142 9%, including spontaneous resolution without catheter ablation in 34%.

143 We analyzed results of radiofrequency catheter ablation in a large cohort of patients with CHD

144 mic drug therapy, electric cardioversion, or catheter ablation in comparison with men.

145 art disease and discuss the evolving role of catheter ablation in decreasing ventricular arrhythmia r

146 ent is considered a promising alternative to catheter ablation in patients affected by severe heart a

147 nts recurrent atrial fibrillation (AF) after catheter ablation in patients with AF and a high symptom

148 With Ablation) did not reveal any benefit of catheter ablation in patients with AF and advanced HF.

149 Catheter ablation in patients with heart failure with re

150 for AF termination and long-term success of catheter ablation in patients with persistent AF is at l

151 idence on the long-term clinical benefits of catheter ablation in patients with persistent atrial fib

152 nital heart disease (CHD) and the outcome of catheter ablation in this population have not been studi

153 ne the ventricular substrate and outcomes of catheter ablation in this population.

154 s refractory to medications and conventional catheter ablation, intramural needle radiofrequency abla

155 Catheter ablation is an effective nonpharmacological alt

156 Catheter ablation is an important therapeutic option in

157 Catheter ablation is an increasingly used treatment for

158 Catheter ablation is an increasingly utilized treatment

159 In these patients, catheter ablation is considered for symptom management o

160 l of one or more antiarrhythmic drugs before catheter ablation is considered in patients with atrial

161 Catheter ablation is effective for eliminating most drug

162 Catheter ablation is effective in restoring sinus rhythm

163 Catheter ablation is effective in terminating VT storm a

164 This study demonstrates that the outcome of catheter ablation is favorable in patients with simple C

165 Catheter ablation is increasingly used as a first-line t

166 lation that has not responded to medication, catheter ablation is more effective than antiarrhythmic

167 Catheter ablation is more effective than drug therapy in

168 the pulmonary veins from the left atrium by catheter ablation is superior to antiarrhythmic drug the

169 Catheter ablation is the most efficacious approach to er

170 ve control of FAT with medications; however, catheter ablation is used for most patients.

171 Radiofrequency catheter ablation is used to treat recurrent ventricular

172 In the meantime, catheter ablation is widely used for the treatment of pe

173 Its use during radiofrequency catheter ablation may allow the operator to assess the d

174 Irrigated microwave catheter ablation may be an effective ablation modality

175 In these individuals, catheter ablation may be used as adjunctive therapy to t

176 he study was limited by absence of blinding, catheter ablation may offer an advantage for quality of

177 Patients with prior PM VAs catheter ablation (N=33/66 PMs) were prospectively evalu

178 amiodarone [n=103] or sotalol [n=78]) and AF catheter ablation (n=49) or the Maze procedure at surgic

179 of asymptomatic patients who did not undergo catheter ablation (n=883, with follow-up ranging from 8

180 ctroporation seems to be a safe modality for catheter ablation near the esophagus.

181 Despite the existing data on AF catheter ablation, numerous knowledge gaps remain concer

182 th drug-refractory AF referred for the first catheter ablation of AF (62.2+/-10 years, 40% nonparoxys

183 ated deaths during index admission following catheter ablation of AF have been reported to be low, ad

184 The effect of catheter ablation of AF in patients with HF may be affec

185 AF and LVEF <=35% were randomly allocated to catheter ablation of AF or best medical therapy (BMT).

186 risk alleles predict recurrence of AF after catheter ablation of AF.

187 rigated radiofrequency ablation (RFA) during catheter ablation of AF.

188 describe a novel individualized approach for catheter ablation of atrial fibrillation (AF) based on l

189 e prediction of arrhythmia recurrences after catheter ablation of atrial fibrillation (AF) remains ch

190 iatrial fat tissue predicts recurrence after catheter ablation of atrial fibrillation (AF).

191 Catheter ablation of atrial fibrillation (AFCA) is an es

192 al trial conducted at 5 referral centers for catheter ablation of atrial fibrillation in the Russian

193 Catheter ablation of atrial fibrillation is associated w

194 However, catheter ablation of atrial fibrillation should be consi

195 Catheter ablation of atrial fibrillation using thermal e

196 Among studies of radiofrequency catheter ablation of atrial fibrillation, high success r

197 ) of atrial tachyarrhythmia are common after catheter ablation of atrial fibrillation.

198 ers have demonstrated improved outcome after catheter ablation of atrial fibrillation.

199 dage (LAA) isolation (LAAI) may occur during catheter ablation of atrial tachyarrhythmias.

200 Cumulatively, catheter ablation of AVNRT continued to be effective in

201 n anatomic obstacles preclude radiofrequency catheter ablation of idiopathic ventricular arrhythmias

202 n, and hence predict safety and efficacy for catheter ablation of OT ventricular arrhythmias.

203 11 years; 17 male) undergoing radiofrequency catheter ablation of paroxysmal atrial fibrillation to r

204 paroxysmal atrial fibrillation who underwent catheter ablation of paroxysmal atrial fibrillation.

205 (The Randomized Catheter Ablation of Persist End Atrial Fibrillation Stu

206 tic factors for arrhythmia recurrences after catheter ablation of persistent AF using the stepwise ap

207 Catheter ablation of persistent AF using the stepwise ap

208 Catheter ablation of persistent atrial fibrillation (AF)

209 novations have been introduced to facilitate catheter ablation of post-myocardial infarction ventricu

210 ion of systolic dysfunction after successful catheter ablation of PVCs demonstrates that a causal rel

211 (AHD) in patients undergoing radiofrequency catheter ablation of scar-related ventricular tachycardi

212 in 11% of patients undergoing radiofrequency catheter ablation of scar-related VT and is associated w

213 nsecutive patients undergoing radiofrequency catheter ablation of scar-related VT.

214 the multicenter experience with percutaneous catheter ablation of sustained monomorphic ventricular t

215 Radiofrequency catheter ablation of the apical LVS-VAs was successful i

216 The catheter ablation of the parietal band VAs was always ch

217 Catheter ablation of the slow conducting pathway (SP) is

218 ed to be able to improve the outcomes of the catheter ablation of those VAs by the anatomic approach.

219 idiopathic LVS-VAs, which could mislead the catheter ablation of those VAs.

220 g extracorporeal membrane oxygenation during catheter ablation of unstable ventricular tachycardia (V

221 study compares outcomes and complications of catheter ablation of VA from the papillary muscles of th

222 Catheter ablation of ventricular tachycardia (VT) in arr

223 Data on outcomes after catheter ablation of ventricular tachycardia (VT) in pat

224 localizing the origin of arrhythmias during catheter ablation of ventricular tachycardia (VT) in str

225 Background Catheter ablation of ventricular tachycardia (VT) in str

226 Catheter ablation of ventricular tachycardia (VT) is bei

227 Epicardial radiofrequency catheter ablation of ventricular tachycardia remains cha

228 Catheter ablation of VT among LVAD recipients is feasibl

229 Catheter ablation of VT associated with LMNA cardiomyopa

230 l heart disease who underwent radiofrequency catheter ablation of VT in 2 centers were included.

231 med to investigate the effects of successful catheter ablation of VT on cardiac mortality in patients

232 During catheter ablation of VT, simultaneous mapping was perfor

233 e investigated the effect of restoring SR by catheter ablation on left ventricular (LV) function and

234 ervative estimate of the treatment effect of catheter ablation on mortality (hazard ratio of 0.86), t

235 were the cost of ablation and the effect of catheter ablation on mortality reduction.

236 eate deep lesions and is a safe modality for catheter ablation on or near coronary arteries.

237 near model were used to assess the impact of catheter ablation on VF episodes.

238 04 patients with atrial fibrillation (AF) to catheter ablation or drug therapy.

239 l tachycardia) between 91 and 365 days after catheter ablation or the initiation of an antiarrhythmic

240 oke reduction benefit of rhythm control with catheter ablation over a rate control strategy.

241 atients <18 years of age with CHD undergoing catheter ablation over an 11-year period (2007-2018) wer

242 studies have demonstrated the superiority of catheter ablation over pharmacological therapy for maint

243 y vein isolation versus single tip wide area catheter ablation-paroxysmal atrial fibrillation is the

244 AF burden was also significantly reduced in catheter ablation patients, regardless of their baseline

245 to-treat analysis, 54 were randomly assigned catheter ablation plus ICD implantation (ablation group:

246 Achieving a combined catheter ablation procedural end point of VT noninducibi

247 Patients who failed at least one prior catheter ablation procedure for sustained ventricular ta

248 etween the first diagnosis of PersAF and the catheter ablation procedure had a strong association wit

249 success rates are still major limitations of catheter ablation procedures for the treatment of atrial

250 In 19 patients undergoing 21 catheter ablation procedures of scar-related VT, site of

251 n 62% of patients) undergoing 74 unstable VT catheter ablation procedures.

252 Radiofrequency catheter ablation reduced implantable cardioverter-defib

253 fibrillation undergoing PVI from the Swedish Catheter Ablation Register were included, with informati

254 patient-years) with 81% off anticoagulation, catheter ablation reinterventions in 13 patients for atr

255 Catheter ablation resulted in complete procedural succes

256 gical testing with or without radiofrequency catheter ablation (RFA).

257 tral isthmus (MI) block using radiofrequency catheter ablation (RFCA) alone is challenging, and MI re

258 Radiofrequency catheter ablation (RFCA) of idiopathic ventricular arrhy

259 Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT)

260 Maintenance of sinus rhythm with drugs or catheter ablation should be considered based on the indi

261 ses that can be transected by radiofrequency catheter ablation similar to isthmus block for atrial fl

262 We sought to compare the effect of a catheter ablation strategy with that of a medical rate c

263 Studies of patients presenting for catheter ablation suggest that premature ventricular con

264 When a standard catheter ablation targeting the best electrophysiologica

265 tiarrhythmic drugs and standard percutaneous catheter ablation techniques portends a poor prognosis.

266 tiarrhythmic drugs and standard percutaneous catheter ablation techniques.

267 Specifically, the advances in catheter ablation technology and strategies have not tra

268 ropriate ICD shock among patients undergoing catheter ablation than among those receiving an escalati

269 wall enhancement) predicts poor response to catheter ablation therapy for AF.

270 Although catheter ablation therapy for atrial fibrillation (AF) i

271 Catheter ablation therapy, commonly used in the treatmen

272 ofrequency instruments, required endocardial catheter ablation to complete the linear ablation lesion

273 he Evaluate Renal Denervation in Addition to Catheter Ablation to Eliminate Atrial Fibrillation (ERAD

274 Twelve patients (15%) underwent safe catheter ablation under venoarterial extracorporeal memb

275 The initial 57 patients (group A) underwent catheter ablation using a novel superolateral MIL design

276 m safety and effectiveness of radiofrequency catheter ablation using an open-irrigated catheter.

277 atients with persistent AF underwent de novo catheter ablation using the stepwise approach (2007-2009

278 The CABANA (Catheter Ablation Versus Antiarrhythmic Drug Therapy for

279 ting the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outco

280 (Catheter Ablation Versus Medical Rate Control in Atrial

281 (Catheter Ablation vs Anti-arrhythmic Drug Therapy for At

282 DESIGN, SETTING, AND PARTICIPANTS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atr

283 : An open-label randomized clinical trial of catheter ablation vs drug therapy in 2204 symptomatic pa

284 However, the estimated treatment effect of catheter ablation was affected by lower-than-expected ev

285 Catheter ablation was associated with 6.47 (95% CI, 5.89

286 Catheter ablation was associated with a highly significa

287 AF catheter ablation was associated with an increased risk

288 The change in VF events before and after catheter ablation was compared with matched controls wit

289 Catheter ablation was effective in reducing recurrence o

290 Bottom Line: Radiofrequency catheter ablation was found to be superior to antiarrhyt

291 Catheter ablation was guided by activation/entrainment m

292 Catheter ablation was successful in 10 patients, and VAs

293 Catheter ablation was superior to conventional drug ther

294 recurrent ventricular tachycardia undergoing catheter ablation, we retrospectively analyzed electrogr

295 l tachyarrhythmias undergoing radiofrequency catheter ablation were classified according to complexit

296 ) aged 18 to 80 years, scheduled for de novo catheter ablation, were eligible.

297 Although catheter ablation will benefit patients with predominant

298 al, untreated atrial fibrillation to undergo catheter ablation with a cryothermy balloon or to receiv

299 Catheter ablation with substrate modification is effecti

300 discrete radiofrequency lesion delivery via catheter ablation without concomitant use of an electroa